Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
SOPHIA ANTIPOLIS, France, Aug. 10, 2016 -- Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic company, today announced the completion of the transfer of its European and International commercial operations and related late-stage development programs to a newly-founded, private, pan-European ophthalmic specialty pharmaceutical company. This transfer includes the affiliates Nicox Pharma (France), together with its Spanish and UK operations, Nicox GmbH (Germany), Laboratoires Nicox (France) and Nicox Farma (Italy), all commercial products and the rights (and associated agreements) to AzaSite®, AzaSite Xtra®, BromSiteTM for Europe, Middle East and Africa and NCX 4240 outside of Japan and North America. No other Nicox affiliates, operations or programs are included in or affected by this transaction.
Nicox will receive a €9 million cash payment from GHO Capital as a result of the completion of this transaction. For further information on the transaction, please refer to Nicox's Press Release dated July 5, 2016.
...................................
About Nicox
Nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is an international R&D company focused on the ophthalmic market. For more information on Nicox, its products or pipeline, please visit: www.nicox.com.
...................................
|
Analyst coverage Bryan, Garnier & Co Hugo Solvet Paris, France Invest Securities Martial Descoutures Paris, France Gilbert Dupont Damien Choplain Paris, France Stifel Max Hermann London, UK |
Upcoming financial and business conferences
September 11-13 Rodman & Renshaw Annual Global Investment Conference New York, US
October 5-6 Large & Midcap Event Paris, France
November 15-16 Stifel 2016 Healthcare Conference New York, US
November 18-19 Actionnaria Paris, France
November 21-23 Deutsches Eigenkapitalforum Frankfurt, Germany
December 13 Guggenheim Securities 4th Annual Boston Healthcare Conference Boston, US
...................................
Contacts
Nicox Gavin Spencer | Executive Vice President Corporate Development
Tel +33 (0)4 97 24 53 00 | [email protected]
Media Relations
United Kingdom Jonathan Birt
Tel +44 7860 361 746 | [email protected]
France NewCap | Nicolas Merigeau
Tel +33 (0)1 44 71 94 98 | [email protected]
United States Argot Partners | Eliza Schleifstein
Tel +1 (917) 763-8106 | [email protected]
Investor Relations
Europe NewCap | Julien Perez | Valentine Brouchot
Tel +33 (0)1 44 71 94 94 | [email protected]
United States Argot Partners | Melissa Forst
Tel +1 (212) 600-1902 | [email protected]
...................................
The information contained in this document may be modified without former notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.
Press release http://hugin.info/143509/R/2034162/757530.pdf
HUG#2034162
